NewEdge Wealth’s Fennec Pharmaceuticals FENC Stock Holding History

NewEdge Wealth’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,000	Closed	-$96K	–	623
2022 Q4	$96K	Buy	+10,000	New	+$88.5K	﹤0.01%	531

Other funds holding FENC

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

NewEdge Wealth's FENC Position: Q1 2023 in Review

NewEdge Wealth sold out of Fennec Pharmaceuticals (FENC) in Q1 2023, closing a stake of 10,000 shares — an estimated $96K sold.

NewEdge Wealth first reported a position in FENC in Q4 2022 and held it in 1 quarter. The position peaked at $96K in Q4 2022. 53 funds tracked by Wall St. Rank hold FENC as of Q1 2023.

NewEdge Wealth reported no remaining Fennec Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
NewEdge Wealth sold 10,000 Fennec Pharmaceuticals shares in Q1 2023, an estimated $96K.
NewEdge Wealth first reported a position in Fennec Pharmaceuticals in Q4 2022 and held it in 1 quarter.
NewEdge Wealth's Fennec Pharmaceuticals position peaked at $96K in Q4 2022.
53 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2023.

Based on NewEdge Wealth's 13F filing for Q1 2023, filed 8 May 2023.